Cytek Biosciences, Inc. Quarterly Report Released - Here’s What You Should Know

Cytek Biosciences, Inc. Quarterly Report Summary (Quarter Ended September 30, 2025)

Financial Performance:

• Revenue: Q3 2025 total revenue was $52.3M (up 2% YoY); YTD total revenue was $139.4M (down 3% YoY).
  • Product revenue for Q3 2025: $38.1M (down 4% YoY); YTD: $97.6M (down 10% YoY).
  • Service revenue for Q3 2025: $14.2M (up 19% YoY); YTD: $41.7M (up 20% YoY).
• Gross Profit & Margin: Q3 2025 gross profit was $27.6M (margin 53%, down from 56% YoY); YTD gross profit $71.6M (margin 51%, down from 54% YoY).
  • Margin decline was primarily driven by lower service gross margins (higher labor and travel costs) and lower product margins.
• Operating Loss: Q3 2025 operating loss was $9.2M (vs. $4.2M loss YoY); YTD operating loss $34.8M (vs. $23.5M loss YoY).
• Net Loss: Q3 2025 net loss was $5.5M (vs. $0.9M net income YoY); YTD net loss $22.5M (vs. $15.7M net loss YoY).
  • Net loss per share, basic and diluted: Q3 2025: $(0.04), YTD: $(0.18).
• Operating Expenses: Q3 2025 operating expenses rose to $36.7M (from $33.3M YoY); YTD $106.4M (from $101.0M YoY).
  • General and administrative expenses increased by 47% in Q3 to $16.1M; YTD they rose 25% to $42.6M. R&D and sales/marketing spend declined YoY.
• Cash Position: Cash, cash equivalents, and marketable securities were $261.7M as of September 30, 2025 (down from $277.9M at FY 2024).
• Cash Flows: YTD net cash used in operating activities was $(3.9)M (compared to $23.4M provided in YTD 2024). Investing provided $12.0M (YTD 2024: used $19.5M). Financing used $(12.2)M (similar to YTD 2024).

Balance Sheet:

• Total assets: $494.9M (down from $499.5M at 12/31/24).
• Total liabilities: $116.3M (up from $103.8M at 12/31/24).
• Stockholders’ equity: $378.6M (down from $395.7M at 12/31/24).
• Share count: 127,864,830 common shares outstanding as of 10/31/25.

Key Business Developments:

• Revenue was stable, but product sales declined as academic/government demand softened (Q3 down $3.4M YoY).
• Service revenue continued to grow with a 19% YoY increase in Q3.
• International revenue: U.S. $27.2M; EMEA $12.4M; APAC $11.1M; Other $1.6M in Q3.
• Company continues global expansion and invests in new product development; R&D spend remains significant.
• Ongoing share repurchase program: ~13.9M shares repurchased under three programs.

Risks & Uncertainties:

• Limited operating history and recent commercial product launch may cloud visibility on long-term performance.
• Heavy reliance on a small number of products (Cytek Aurora lines contributed a substantial portion of revenue).
• Single/sole source suppliers pose supply-chain risks.
• Business and financial performance exposed to:
  • Fluctuations in academic/government funding (34% of Q3 2025 revenue from these customers).
  • International regulatory, operational, and political risks (manufacturing in U.S., China, Singapore; global sales).
  • Tariff/trade policy and new U.S. export controls, particularly those affecting China business.
  • Competition in cell analysis/life sciences market is intense, with larger, better-capitalized players.
• Internal control material weaknesses identified in FY2024 are not yet fully remediated, posing risks to reliability of financial reporting.
• Future capital needs may arise if losses persist; cash burn continued in 2025.
• Potential product liability, intellectual property, data security, and regulatory compliance risks.
• Stock price may be volatile due to company-specific and broader market factors; no dividend expected.

Liquidity & Capital Resources:

• Strong liquidity position; management believes current cash and equivalents are sufficient for ongoing needs.
• No off-balance sheet arrangements as of reporting date.

Conclusion: Cytek’s financials reflect stable but pressured revenue, declining product sales offset by strong service growth, compressed margins, and continued operating losses driven by both cost of sales and higher general/admin expenses. The company maintains a solid liquidity position but faces significant execution, operational, competitive, and control-related risks. Investors should closely monitor ongoing trends in academic/government funding, competitive dynamics, export controls, internal control remediation, and the company’s ability to achieve profitable growth.

Visit Publicview AI to search and analyze millions of SEC filings using AI.